Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.35 |
| ▸ | IDH1 | O75874 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NGF | P01138 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12870971 | 0.87 | HCRTR1 (0.36) | HCRTR1HCRTR2MEN1MAPTKMT2A | |
| SCHEMBL12871022 | 0.86 | KDM4E (0.31) | MEN1KMT2A | |
| SCHEMBL12871013 | 0.85 | HCRTR1 (0.36) | HCRTR1HCRTR2IDH1MEN1MAPT | |
| SCHEMBL12870994 | 0.85 | KDM4E (0.39) | HCRTR1HCRTR2MEN1MAPTKMT2A | |
| SCHEMBL12870488 | 0.84 | HDAC1 (0.42) | MEN1MAPTKMT2A | |
| SCHEMBL12870947 | 0.82 | HDAC1 (0.46) | IDH1 | |
| SCHEMBL12871035 | 0.81 | HCRTR1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL14533015 | 0.77 | HCRTR1 (0.33) | HCRTR1HCRTR2IDH1MEN1TDP2 | |
| SCHEMBL12870909 | 0.75 | IP6K1 (0.41) | IDH1MAPTRECQLKMT2A | |
| SCHEMBL12871004 | 0.75 | HCRTR1 (0.36) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | HCRTR1 3215/4885HCRTR2 4027/4885IDH1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.